Samsung Gains Interest from BYD, Google, AMD as AI Chip Demand Strains TSMC Capacity 
Saudi Aramco Explores Sulphur Business Stake Sale to Raise Billions 
BHP Shares Fall as Jansen Potash Project Costs Surge 
Obayashi to Acquire Multiplex in $526M Expansion Deal 
Apple Signals Product Price Hikes Amid Rising Memory Chip Costs 
Kingboard Holdings Shares Surge After HK$11.77 Billion Block Trade to Expand PCB and AI Supply Chain Business 
Chinese Social Media Giant Xiaohongshu Eyes Hong Kong IPO at Over $70 Billion Valuation 
Hyundai to Acquire SoftBank’s Remaining Boston Dynamics Stake for $325 Million 
GM and Lockheed Martin Partner to Strengthen U.S. Defense Manufacturing Capacity 
China Adds MP Materials, USA Rare Earth to Export Control List Amid Escalating U.S.-China Trade Tensions 
Google’s Open-Source AI Data Center Cooling Design Raises Commoditization Concerns 
Qantas Unveils Wellness-Focused Nonstop Sydney-London Flights to Reduce Jet Lag 
Carro Expands Into Australia With Acquisition of Used-Car Platform CarPlace 
Jio IPO Filing Nears as Reliance Targets $4 Billion Market Debut 
Meta Seeks Legal Shield From Child-Harm Lawsuits Amid KOSA Talks 
US Raises Concerns Over Possible ASML EUV Machine Transfer to China 
Ukrainian Drone Makers Target Japan and Asia Defense Market 
YAVNE, Israel, Jan. 19, 2016 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq:MDWD), a fully-integrated, biopharmaceutical company bringing innovative therapies to address unmet needs in severe burn and wound management, today announced that the Company will release financial results for the three and twelve months ended December 31, 2015, at 7:00 a.m. Eastern time on January 25, 2016.
Following the release, MediWound's management will host a conference call for the investment community beginning at 8:30 a.m. ET on Monday, January 25, 2016, to discuss the financial results and to answer questions.
Shareholders and other interested parties may participate in the conference call by dialing (877) 280-2296 (domestic) or (1809) 212-925 (Israel) and entering passcode 8854485. The call also will be broadcast live on the Internet on the Company’s website at www.mediwound.com.
A replay of the call will be accessible two hours after its completion through February 1, 2016 by dialing (866) 932-5017 (domestic) or (800) 358-7735 (UK) and entering passcode 8854485. The call will also be archived on the Company website for 90 days at www.mediwound.com.
About MediWound Ltd.
MediWound is a fully integrated biopharmaceutical company focused on developing, manufacturing and commercializing novel therapeutics based on its patented proteolytic enzyme technology to address unmet needs in the fields of severe burns, chronic and other hard-to-heal wounds. MediWound’s first innovative biopharmaceutical product, NexoBrid, received marketing authorization from the European Medicines Agency for removal of dead or damaged tissue, known as eschar, in adults with deep partial and full-thickness thermal burns and was launched in Europe. NexoBrid represents a new paradigm in burn care management, and clinical trials have demonstrated, with statistical significance, its ability to non-surgically and rapidly remove the eschar earlier and, without harming viable tissues. For more information, please visit www.mediwound.com.
Contacts: Sharon Malka Chief Financial and Operations Officer MediWound [email protected] Anne Marie Fields Senior Vice President LHA 212-838-3777 [email protected]
